• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form N-PX filed by Sanofi

    7/30/25 8:09:49 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    Form N-PX Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM N-PX
    ANNUAL REPORT OF PROXY VOTING RECORD
    OMB APPROVAL


    Form N-PX

    OMB Number:  3235-0582


    Estimated average burden hours per response: 20.8

    N-PX: Filer Information

    Filer CIK
    0001121404 
    Filer CCC
    ********  
    Date of Report
    06/30/2025 
    Are you a Registered Management Investment Company or an Institutional Manager?
    Institutional Manager 
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Is this an electronic copy of an official filing submitted in paper format? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone Number
     
    E-mail Address
     

    Notification Information

    Notify via Filing Website only?Checkbox not checked

    N-PX: Cover Page

    Name and address of reporting person:

    Name of reporting person (For registered management investment companies, provide exact name of registrant as specified in charter)

    Sanofi 

    Street 1

    46 Avenue de la Grande Armee 

    Street 2

     

    City

    Paris 

    State/Country

    FRANCE  

    Zip code and zip code extension or foreign postal code

    75017 

    Telephone number of reporting person, including area code:

    33-1-53-77-44-00 

    Name and address of agent for service:

    Name of agent for service

    Sanofi U.S. Services Inc. 

    Street 1

    55 Corporate Drive 

    Street 2

     

    City

    Bridgewater 

    State/Country

    NEW JERSEY  

    Zip code and zip code extension or foreign postal code

    08807 

    Reporting Period:Report for the year ended June 30, 2025 
    SEC Investment Company Act or Form 13F File Number:

    028-25202 

    CRD Number (if any):

     

    Other SEC File Number (if any):

     

    Legal Entity Identifier (if any):

     

    Report Type (check only one):

    Registered Management Investment Company.
    Radio button not checked Fund Voting Report (Check here if the registered management investment company held one or more securities it was entitled to vote.)
    Radio button not checked Fund Notice Report (Check here if the registered management investment company did not hold any securities it was entitled to vote.)
    Institutional Manager.
    Radio button not checked Institutional Manager Voting Report (Check here if all proxy votes of this reporting manager are reported in this report.)
    Radio button checked Institutional Manager Notice Report (Check here if no proxy votes are reported in this report and complete the notice report filing explanation section below)
    Notice report filing explanation:
    Radio button not checked All proxy votes for which the manager exercised voting power are reported by other reporting persons
    Radio button checked The reporting person did not exercise voting power for any reportable voting matter
    Radio button not checked The reporting person has a clearly disclosed policy of not voting and did not vote on any proxy voting matters
    Radio button not checked Institutional Manager Combination Report (Check here if a portion of the proxy votes for this reporting manager are reported in this report and a portion are reported by other reporting person(s).)
    Do you wish to provide explanatory information pursuant to Special Instruction B.4?: Radio button not checked Yes Radio button checked No
    Additional information:

     

    N-PX: Summary - Included Managers

    Number of Included Institutional Managers:

    0 

    Included Institutional Managers:NONE

    N-PX: Signature Block

    Reporting Person:

    Sanofi 

    By (Signature):

    Alexandra Roger 

    By (Printed Signature):

    Alexandra Roger 

    By (Title):

    Head of Legal Corporate & Finance 

    Date:

    07/30/2025 

    Get the next $SNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    1/27/2026Neutral
    Citigroup
    1/16/2026Buy → Neutral
    UBS
    1/6/2026Overweight → Equal Weight
    Barclays
    12/9/2025Buy → Neutral
    Guggenheim
    12/8/2025Overweight → Neutral
    Analyst
    9/8/2025$58.00Equal-Weight → Overweight
    Morgan Stanley
    9/2/2025Hold → Buy
    Deutsche Bank
    8/8/2025Neutral → Overweight
    Analyst
    More analyst ratings

    $SNY
    SEC Filings

    View All

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    2/6/26 10:09:38 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Sanofi

    S-8 POS - Sanofi (0001121404) (Filer)

    2/5/26 6:17:47 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    1/29/26 8:56:13 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezurock® now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)

    Three provinces now cover Rezurock® (belumosudil) through their provincial formularies for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy1A significant step forward for chronic GVHD patients and their families following Health Canada approval (March 2023) and Canada's Drug Agency (CDA-AMC) recommendation in March 2024Chronic GVHD is a serious complication following stem cell transplant, with debilitating symptoms that can last for years2TORONTO, Feb. 3, 2026 /CNW/ - British Columbia and Ontario recently added Rezurock® (belumosudil) to their provincial formularies for adult and pediat

    2/3/26 8:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy

    – New collaboration builds on Sanofi's prior acquisition of DR-0201 and further leverages Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class multispecific antibody therapeutics – – Dren Bio will receive an upfront cash payment of $100 million and is also eligible to receive up to $1.7 billion in future development, regulatory, and commercial milestone payments – – Dren Bio retains the option to co-fund future development in exchange for U.S. co-promotion rights with Sanofi, a 50/50 share of U.S. profits and losses, and milestones plus tiered royalties on ex-U.S. sales – Dren Bio, a privately held, clinical-stage biotechnology company deve

    12/15/25 8:05:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

    Halda Therapeutics acquired by Johnson & Johnson for $3.05 billion – the largest acquisition ever across any therapeutic area for a Phase 1 company Scorpion Therapeutics acquired by Eli Lilly for Up to $2.5 billion - one of the highest-value strategic transactions announced in early 2025 Vigil Neuroscience acquired by Sanofi for a $470 million upfront plus contingent value right (CVR) - advancing a potential breakthrough in Alzheimer's disease Capstan Therapeutics acquired by AbbVie for a record-breaking $2.1 billion – the highest ever for a company with only healthy-volunteer data Halda and Capstan each broke industry records in 2025, marking a historic year for Vida and under

    11/17/25 6:07:00 PM ET
    $ABBV
    $JNJ
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Sanofi

    Citigroup initiated coverage of Sanofi with a rating of Neutral

    1/27/26 8:49:24 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by UBS

    UBS downgraded Sanofi from Buy to Neutral

    1/16/26 8:32:26 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by Barclays

    Barclays downgraded Sanofi from Overweight to Equal Weight

    1/6/26 11:55:33 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

    4 - Sanofi (0001121404) (Reporting)

    8/2/21 8:34:24 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Sanofi

    3 - Sanofi (0001121404) (Reporting)

    7/28/21 8:32:04 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

    6/2/25 1:25:00 AM ET
    $BPMC
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

    5/21/25 7:30:46 PM ET
    $SNY
    $VIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sanofi

    SC 13G/A - Sanofi (0001121404) (Subject)

    11/7/24 2:49:36 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sanofi

    SC 13G - Sanofi (0001121404) (Filed by)

    5/31/24 4:30:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sanofi (Amendment)

    SC 13G/A - Sanofi (0001121404) (Subject)

    2/14/24 3:57:49 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Leadership Updates

    Live Leadership Updates

    View All

    ITM Appoints Annette Breunig as Chief People Officer

    Global HR leader to drive ITM's long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief People Officer (CPO). Ms. Breunig brings over 25 years of HR leadership experience at international pharmaceutical, manufacturing and technology companies, including at Siemens AG (FRA: SIE) and Sanofi (NASDAQ:SNY). At ITM, Ms. Breunig will lead the HR team in shaping strategies that unify the organization to achieve both team and business growth objectives while empowering em

    10/13/25 5:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

    TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

    6/9/25 10:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care